Table 5 Adherence to clinical standards for management of obstetric complications
Use of uterotonics for Prevention of postpartum haemorrhage | |
|---|---|
Target population women giving birth at DH | N1 = 511a |
Oxytocin | 485 (94.9%) |
Misoprostol | 7 (1.4%) |
All uterotonics | 492 (96.3%) |
Treatment of PPH | |
Target population women severe PPH | N2 = 58 |
Oxytocin | 38 (65.5%) |
Oxytocin/Removal of retained placenta | 7 (12.1%) |
Oxytocin/Misoprostol | 3 (5.2%) |
Misoprostol | 1 (1.7%) |
Hysterectomy | 6 (10.3%) |
Use of anticonvulsants | |
Target population women with severe (pre-) eclampsia | N3 = 19 |
Magnesium sulfate | 18 (94.7%) |
Diazepam | 1 (5.3%) |
Prevention of caesarean section /laparotomy related infection | |
Target population undergoing Caesarean section/laparotomy | N4 = 300b |
Prophylactic antibiotics | 456 (98.6%) |
Treatment of sepsis | |
Target population women with sepsis | N5 = 15 |
Parenteral therapeutic antibiotics | 15 (100%) |